Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E, Elemento O, Chang J, Inghirami G, Gao D, Ryu S, Mittal V.

Cell Rep. 2020 Jan 21;30(3):755-770.e6. doi: 10.1016/j.celrep.2019.12.056.

2.

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

Sailer V, Eng KW, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E, Cyrta J, Rao R, Sahota S, Pauli C, Beg S, Motanagh S, Kossai M, Fontunge J, Puca L, Rennert H, Zhaoying Xiang J, Greco N, Kim R, MacDonald TY, McNary T, Blattner-Johnson M, Schiffman MH, Faltas BM, Greenfield JP, Rickman D, Andreopoulou E, Holcomb K, Vahdat LT, Scherr DS, van Besien K, Barbieri CE, Robinson BD, Fine HA, Ocean AJ, Molina A, Shah MA, Nanus DM, Pan Q, Demichelis F, Tagawa ST, Song W, Mosquera JM, Sboner A, Rubin MA, Elemento O, Beltran H.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00047. Epub 2019 Sep 20.

3.

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.

Schwartzberg L, McIntyre K, Wilks S, Puhalla S, O'Shaughnessy J, Berrak E, He Y, Vahdat L.

BMC Cancer. 2019 Jun 13;19(1):578. doi: 10.1186/s12885-019-5674-5.

4.

Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis.

Silberholz J, Bertsimas D, Vahdat L.

Breast Cancer Res Treat. 2019 Aug;176(3):535-543. doi: 10.1007/s10549-019-05208-w. Epub 2019 May 14.

PMID:
31089928
5.

Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.

Kehm RD, Hopper JL, John EM, Phillips KA, MacInnis RJ, Dite GS, Milne RL, Liao Y, Zeinomar N, Knight JA, Southey MC, Vahdat L, Kornhauser N, Cigler T, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators, Andrulis IL, Buys SS, Daly MB, Terry MB.

Breast Cancer Res. 2019 Apr 18;21(1):52. doi: 10.1186/s13058-019-1135-y.

6.

Copper Depletion as a Therapeutic Strategy in Cancer.

Lopez J, Ramchandani D, Vahdat L.

Met Ions Life Sci. 2019 Jan 14;19. pii: /books/9783110527872/9783110527872-018/9783110527872-018.xml. doi: 10.1515/9783110527872-018. Review.

PMID:
30855113
7.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
8.

Functional Peptide Nanofibers with Unique Tumor Targeting and Enzyme-Induced Local Retention Properties.

Bellat V, Ting R, Southard TL, Vahdat L, Molina H, Fernandez J, Aras O, Stokol T, Law B.

Adv Funct Mater. 2018 Oct 31;28(44). pii: 1803969. doi: 10.1002/adfm.201803969. Epub 2018 Sep 14.

9.

Personalized Nutrition in Disrupting Cancer - Proceedings From the 2017 American College of Nutrition Annual Meeting.

Wallace TC, Bultman S, D'Adamo C, Daniel CR, Debelius J, Ho E, Eliassen H, Lemanne D, Mukherjee P, Seyfried TN, Tian Q, Vahdat LT.

J Am Coll Nutr. 2019 Jan;38(1):1-14. doi: 10.1080/07315724.2018.1500499. Epub 2018 Dec 4. Erratum in: J Am Coll Nutr. 2019 Sep-Oct;38(7):659.

PMID:
30511901
10.

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ.

J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21. Erratum in: J Clin Oncol. 2018 Nov 20;36(33):3348. J Clin Oncol. 2019 Feb 1;37(4):362.

11.

Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.

Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L.

Clin Breast Cancer. 2018 Dec;18(6):489-497. doi: 10.1016/j.clbc.2018.07.024. Epub 2018 Aug 4.

PMID:
30153978
12.

A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.

Bao T, Seidman AD, Piulson L, Vertosick E, Chen X, Vickers AJ, Blinder VS, Zhi WI, Li Q, Vahdat LT, Dickler MN, Robson ME, Mao JJ.

Eur J Cancer. 2018 Sep;101:12-19. doi: 10.1016/j.ejca.2018.06.008. Epub 2018 Jul 13.

13.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J.

Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26.

PMID:
29706375
14.

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park BH, Vahdat LT, Leyland-Jones B, Mughal TI, Pusztai L, O'Shaughnessy J, Miller VA, Ross JS, Ali SM.

Ann Oncol. 2017 Nov 1;28(11):2866-2873. doi: 10.1093/annonc/mdx490.

15.

An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.

Walsh LA, Alvarez MJ, Sabio EY, Reyngold M, Makarov V, Mukherjee S, Lee KW, Desrichard A, Turcan Ş, Dalin MG, Rajasekhar VK, Chen S, Vahdat LT, Califano A, Chan TA.

Cell Rep. 2017 Aug 15;20(7):1623-1640. doi: 10.1016/j.celrep.2017.07.052.

16.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM.

Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.

17.

Sacituzumab govitecan: an antibody-drug conjugate.

Sahota S, Vahdat LT.

Expert Opin Biol Ther. 2017 Aug;17(8):1027-1031. doi: 10.1080/14712598.2017.1331214. Epub 2017 May 22. Review.

PMID:
28503956
18.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

19.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

20.

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K.

Oncologist. 2017 Mar;22(3):245-254. doi: 10.1634/theoncologist.2016-0265. Epub 2017 Feb 20.

21.
22.

Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.

Sands S, Ladas EJ, Kelly KM, Weiner M, Lin M, Ndao DH, Dave A, Vahdat LT, Bender JG.

Support Care Cancer. 2017 Mar;25(3):701-708. doi: 10.1007/s00520-016-3441-6. Epub 2016 Nov 9.

23.

Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.

Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, Donovan D, Vallee Cobham M, Fitzpatrick V, Schneider S, Wiener A, Guillaume-Abraham J, Aljom E, Zelkowitz R, Warren JD, Lane ME, Fischbach C, Mittal V, Vahdat L.

Clin Cancer Res. 2017 Feb 1;23(3):666-676. doi: 10.1158/1078-0432.CCR-16-1326. Epub 2016 Oct 21.

24.

Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma.

Sammons S, Brady D, Vahdat L, Salama AK.

Melanoma Manag. 2016 Sep;3(3):207-216. doi: 10.2217/mmt-2015-0005. Epub 2016 Sep 2. Review.

25.

Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties.

Bellat V, Lee HH, Vahdat L, Law B.

Biomacromolecules. 2016 Jun 13;17(6):2040-9. doi: 10.1021/acs.biomac.6b00227. Epub 2016 May 24.

26.

Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.

Giles AJ, Reid CM, Evans JD, Murgai M, Vicioso Y, Highfill SL, Kasai M, Vahdat L, Mackall CL, Lyden D, Wexler L, Kaplan RN.

Cancer Res. 2016 Mar 15;76(6):1335-47. doi: 10.1158/0008-5472.CAN-15-0204. Epub 2015 Dec 30.

27.

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D.

Nature. 2015 Nov 26;527(7579):472-6. doi: 10.1038/nature15748. Epub 2015 Nov 11.

28.

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.

O'Shaughnessy J, McIntyre K, Schwartzberg L, Wilks S, Puhalla S, Berrak E, Song J, Vahdat L.

Springerplus. 2015 Sep 21;4:532. doi: 10.1186/s40064-015-1322-y. eCollection 2015.

29.

Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis.

Seo BR, Bhardwaj P, Choi S, Gonzalez J, Andresen Eguiluz RC, Wang K, Mohanan S, Morris PG, Du B, Zhou XK, Vahdat LT, Verma A, Elemento O, Hudis CA, Williams RM, Gourdon D, Dannenberg AJ, Fischbach C.

Sci Transl Med. 2015 Aug 19;7(301):301ra130. doi: 10.1126/scitranslmed.3010467.

30.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2015 Sep 1;21(17):3870-8. doi: 10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5.

31.

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.

Stanton SE, Ward MM, Christos P, Sanford R, Lam C, Cobham MV, Donovan D, Scheff RJ, Cigler T, Moore A, Vahdat LT, Lane ME, Chuang E.

BMC Cancer. 2015 Apr 11;15:267. doi: 10.1186/s12885-015-1298-6.

32.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT.

J Clin Oncol. 2015 May 10;33(14):1609-19. doi: 10.1200/JCO.2014.56.2959. Epub 2015 Apr 6.

PMID:
25847941
33.

Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.

Cigler T, Isseroff D, Fiederlein B, Schneider S, Chuang E, Vahdat L, Moore A.

Clin Breast Cancer. 2015 Oct;15(5):332-4. doi: 10.1016/j.clbc.2015.01.003. Epub 2015 Jan 26.

PMID:
25749072
34.

Menopause is a determinant of breast adipose inflammation.

Iyengar NM, Morris PG, Zhou XK, Gucalp A, Giri D, Harbus MD, Falcone DJ, Krasne MD, Vahdat LT, Subbaramaiah K, Morrow M, Hudis CA, Dannenberg AJ.

Cancer Prev Res (Phila). 2015 May;8(5):349-58. doi: 10.1158/1940-6207.CAPR-14-0243. Epub 2015 Feb 26.

35.

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A.

Breast Cancer Res Treat. 2015 Jan;149(1):313. doi: 10.1007/s10549-014-3245-7. No abstract available.

36.

Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients.

Ebenezer GJ, Carlson K, Donovan D, Cobham M, Chuang E, Moore A, Cigler T, Ward M, Lane ME, Ramnarain A, Vahdat LT, Polydefkis M.

Ann Clin Transl Neurol. 2014 Sep;1(9):639-49. doi: 10.1002/acn3.90. Epub 2014 Sep 2.

37.

Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy.

Nagar H, Boothe D, Ginter PS, Sison C, Vahdat L, Shin S, Smith M, Chao KS, Nori D, Hayes MK.

Clin Breast Cancer. 2015 Apr;15(2):128-34. doi: 10.1016/j.clbc.2014.09.012. Epub 2014 Nov 11.

PMID:
25459070
38.

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A.

Breast Cancer Res Treat. 2014 Dec;148(3):553-61. doi: 10.1007/s10549-014-3144-y. Epub 2014 Nov 8. Erratum in: Breast Cancer Res Treat. 2015 Jan;149(1):313.

39.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, Vahdat L.

J Clin Oncol. 2014 Nov 10;32(32):3619-25. doi: 10.1200/JCO.2013.52.5683. Epub 2014 Sep 29.

PMID:
25267761
40.

Remodeling of the methylation landscape in breast cancer metastasis.

Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, Chan TA.

PLoS One. 2014 Aug 1;9(8):e103896. doi: 10.1371/journal.pone.0103896. eCollection 2014.

41.

Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.

Wilks S, Puhalla S, O'Shaughnessy J, Schwartzberg L, Berrak E, Song J, Cox D, Vahdat L.

Clin Breast Cancer. 2014 Dec;14(6):405-12. doi: 10.1016/j.clbc.2014.04.004. Epub 2014 Jun 2.

42.

New developments in metastatic breast cancer: integrating recent data into clinical practice.

Perez EA, Rugo HS, Vahdat LT.

Clin Adv Hematol Oncol. 2013;11(10 Suppl 16):1-18; quiz 19.

PMID:
24892840
43.

New developments in metastatic breast cancer: general discussion.

Vahdat LT, Rugo HS, Perez EA.

Clin Adv Hematol Oncol. 2013;11(10 Suppl 16):16-7. No abstract available.

PMID:
24765684
44.

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.

McIntyre K, O'Shaughnessy J, Schwartzberg L, Glück S, Berrak E, Song JX, Cox D, Vahdat LT.

Breast Cancer Res Treat. 2014 Jul;146(2):321-8. doi: 10.1007/s10549-014-2923-9. Epub 2014 Apr 4. Erratum in: Breast Cancer Res Treat. 2014 Jul;146(2):329.

45.

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.

Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, Dutcus CE, Yang J, Seegobin S, O'Shaughnessy J.

Oncologist. 2014 Apr;19(4):318-27. doi: 10.1634/theoncologist.2013-0282. Epub 2014 Mar 28.

46.

Novel data in metastatic breast cancer.

Vahdat LT.

Clin Adv Hematol Oncol. 2013;11(10 Suppl 16):13-5. No abstract available.

PMID:
24637556
47.

Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.

Vahdat LT, Vrdoljak E, Gómez H, Li RK, Bosserman L, Sparano JA, Baselga J, Mukhopadhyay P, Valero V.

J Geriatr Oncol. 2013 Oct;4(4):346-52. doi: 10.1016/j.jgo.2013.07.006. Epub 2013 Aug 23.

PMID:
24472478
48.

Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.

Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P.

Lab Chip. 2014 Jan 7;14(1):147-56. doi: 10.1039/c3lc51039e. Epub 2013 Nov 7.

49.

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA.

Breast Cancer Res Treat. 2013 Oct;141(3):429-35. doi: 10.1007/s10549-013-2704-x. Epub 2013 Sep 26.

50.

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.

Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, Gopalakrishna P, Sparano JA.

Breast Cancer Res Treat. 2013 Jul;140(2):341-51. doi: 10.1007/s10549-013-2574-2. Epub 2013 Jul 23.

Supplemental Content

Loading ...
Support Center